Latest Investigation News

The ACCC has initiated Federal Court proceedings against Dusk Group's subsidiary, alleging supply of button battery products without completed safety testing and breaches of prior undertakings.

Megado Minerals has unveiled compelling magnetic survey results at its Alpartir Silver-Copper-Antimony Project in northern Spain, setting the stage for systematic exploration and drilling pending shareholder approval.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Sunshine Metals has unveiled fresh high-grade gold targets at its Sybil project in Queensland following a comprehensive airborne magnetic and radiometric survey. With rock chip samples hitting 21.6g/t Au at Pancho and drilling set to start imminently, the survey reshapes the exploration landscape across Sybil’s epithermal system.

PYC Therapeutics reports durable retinal gene expression and visual improvements from its PYC-001 candidate in Autosomal Dominant Optic Atrophy, supporting longer dosing intervals and expansion into glaucoma research.

Ballard Mining’s June quarter at Mt Ida delivers promising high-grade gold intercepts and new discoveries, underpinning a robust resource growth strategy backed by a solid cash position.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.

Neurizon Therapeutics has completed enrolment for Regimen I of its HEALEY ALS Platform Trial in under five months, speeding up topline data release to late Q2 2027 and materially de-risking its lead clinical program.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.